Key result
T2D patients exhibit ~74% lower LF power amplitude during reactive hyperemia versus healthy controls.
Why the study?
Variations in cardiovascular autonomic modulation during reactive hyperemia in diabetic patients with and without cardiovascular autonomic neuropathy were not well characterized.
Does the reactive hyperemia test reveal altered cardiovascular autonomic modulation in T2DM patients with and without cardiovascular autonomic neuropathy compared to healthy controls?
Case-Control (n=75)
No
Does the reactive hyperemia test reveal altered cardiovascular autonomic modulation in T2DM patients with and without cardiovascular autonomic neuropathy compared to healthy controls?
The reactive hyperemia test reveals altered temporal dynamics of autonomic activity in diabetic patients, suggesting its potential utility as an early non-invasive marker of autonomic dysfunction.
Answers are grounded in this paper and cite their sources.
May indicate altered autonomic responses during hyperemia in T2DM with CAN; leaves open clinical relevance pending prospective studies.
Purpose The objective of this study was to assess the variations in cardiovascular autonomic modulation during reactive hyperemia in diabetic patients with and without cardiovascular autonomic neuropathy (CAN). Methods The study subjects were 35 patients with T2DM without macrovascular complications of diabetes and 40 age and sex matched healthy subjects as the control group. Electrocardiogram and photoplethysmography recordings were performed at rest and during a reactive hyperemia test, which consisted of a 5‐min arterial occlusion followed by release. Autonomic nervous system function was evaluated using heart rate variability analysis (time‐frequency methods) and the sympathetic skin response. Results Healthy subjects showed a significant increase in low‐frequency (LF) power immediately after vascular release, with an average latency of 339.64 ± 53.86 ms and amplitude of 3467.41 ± 2333.68 ms 2 . In diabetic patients with CAN, the response was faster but less intense (latency: 300.00 ± 20.22 ms, amplitude: 907.15 ± 2688.0 ms 2 ). Diabetic patients without CAN showed a similar latency (300.06 ± 37.64 ms) but the amplitude is overall the lowest (505.73 ± 489.37 ms 2 ). Conclusions The reactive hyperemia test reveals an alteration in the temporal dynamics of autonomic activity, as reflected by the low‐frequency component in heart rate variability analysis, in diabetic patients. These patients exhibit a reduced response amplitude and a faster or reactive response, especially those with cardiovascular autonomic neuropathy, suggesting altered autonomic modulation that could serve as an early marker of autonomic dysfunction.
No takes yet. Share an insight, caveat, or question.
López-Galán et al. (2026) conducted a case-control in Type 2 Diabetes Mellitus (n=75). Type 2 Diabetes Mellitus vs. Healthy subjects was evaluated on Low-frequency (LF) power amplitude during reactive hyperemia (p=<0.05). Type 2 diabetes patients, especially those with cardiovascular autonomic neuropathy, exhibited a significantly reduced amplitude and faster latency of low-frequency power during reactive hyperemia compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: